Additionally, the frequency of diabetic ketoacidosis at presentation increased
FRIDAY, Feb. 4, 2022 (HealthDay News) — There has been a significant increase in the number of type 1 diabetes (T1D) diagnoses in children during the COVID-19 pandemic, according to a study published online Jan. 24 in JAMA Pediatrics.
Bethany L. Gottesman, M.D., from University of California in San Diego, and colleagues performed a six-year retrospective review of medical records to evaluate changes in the incidence of new-onset T1D and the number of children presenting with severe illness at diabetes onset. Comparisons were made from the COVID-19 year (March 19, 2020, to March 18, 2021) and the five years prior (March 19, 2015, to March 18, 2020).
The researchers found that during the COVID-19 year, 187 children were admitted for new-onset T1D versus 119 children admitted the previous year. For July 2020 through February 2021, the number of new diagnoses of T1D exceeded the number of patients anticipated based on a quarterly moving average of the preceding five years (July 2020: 15 diagnoses; 10 forecasted diagnoses; February 2021: 21 diagnoses; 10 forecasted diagnoses). The percentage of patients who presented with diabetic ketoacidosis increased during the COVID-19 years versus the five preceding years, but with no difference in mean age at presentation, body mass index z score, hemoglobin A1c, or percentage of children requiring pediatric intensive care unit admission. There was a significant increase observed in the number of children requiring an insulin infusion at the time of T1D diagnosis (49.7 percent during the COVID-19 pandemic versus 40.7 percent in the preceding five years).
“We reviewed the five-year period before the COVID-19 pandemic to account for annual increases in T1D cases to show that the case rate during the COVID-19 pandemic was higher than expected at our institution,” the authors write.
Maternal Diabetes Linked to Increased Risk for Epilepsy in Offspring
Preexisting Medical Conditions Linked to Range of Botox Injection Complications
Diabetes Linked to Increased Risk for Sudden Cardiac Death
Meta-Analysis IDs Link Between Type 1 Diabetes and Bladder Cancer
Cretostimogene Promising for High-Risk, Non-Muscle-Invasive Bladder Cancer
Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine
Perioperative Enfortumab Vedotin + Pembrolizumab Tied to Improved Outcomes With Bladder Cancer
Sex Hormones Linked to Cardiovascular Events in Men With Type 2 Diabetes